MiMeDB: Showing metabocard for 1D-myo-inositol 1-phosphate (MMDBc0033096)

Record Information

Version

1.0

Status

Detected and Quantified

Creation Date

2021-11-19 04:34:37 UTC

Update Date

2022-12-15 22:51:53 UTC

MiMeDB ID

MMDBc0033096

Metabolite Identification

Common Name

1D-myo-inositol 1-phosphate

Description

myo-Inositol 6-phosphate, also known as I6P or Ins(6)P, belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. Inositol phosphate is an intermediate step in the metabolism of glucose-6-phosphate into myo-inositol. myo-Inositol is synthesized from glucose-6-phosphate (G-6-P) in two steps. First, G-6-P is isomerized by INYNA1 into myo-inositol 1-phosphate, which is then dephosphorylated by IMPA1 to give myo-inositol.

Structure

MOL SDF PDB SMILES InChI

Synonyms

Not Available

Chemical Formula

C₆H₁₃O₉P

Average Molecular Weight

260.135

Monoisotopic Molecular Weight

260.029718997

IUPAC Name

Not Available

Traditional Name

Not Available

CAS Registry Number

15421-51-9

SMILES

Not Available

InChI Identifier

InChI=1S/C6H13O9P/c7-1-2(8)4(10)6(5(11)3(1)9)15-16(12,13)14/h1-11H,(H2,12,13,14)/t1-,2-,3+,4-,5-,6-/m1/s1

InChI Key

INAPMGSXUVUWAF-UOTPTPDRSA-N

Chemical Taxonomy

Functional Ontology

Not Available

Physical Properties

State

Solid

Predicted Properties

Not Available

Spectra

Not Available

Biological Properties

Cellular Locations

Nucleus

Biospecimen Locations

Bladder
Brain
Feces
Kidney
Neuron
Placenta
Platelet
Prostate
Prostate Tissue
Saliva
Skeletal Muscle
Testis

Tissue Locations

Placenta

Associated OMIM IDs

114500 (Colorectal cancer)
610247 (Eosinophilic esophagitis)

Human Proteins and Enzymes

Proteins

#<MetaboliteProteinLink:0x000055b76dc60eb0>

Human Pathways

Pathways

Name	SMPDB/PathBank

Metabolic Reactions

Reaction ID	Precursor	Product	Enzyme	Reaction Type	Data Source	Reference

Health Effects and Bioactivity

Health Outcome/Bioactivity	Metabolite Response/Effect	Related Health Condition	Evidence Type	Measured in Matrix	Data Source	Reference
Prostate cancer		This associated disease is originally imported from HMDB metabolite HMDB0002985 concentration id 57885	Association	Human Prostate Tissue		19212411	details

Microbial Sources

Kingdom	Phylum	Total species	Hosts and Body Sites	Microbial Links
Fungi	Ascomycota	1	Human Feces	Unknown
	Proteobacteria	1

Exposure Sources

Source Type	Source Sub-type	Species	Data Source	Reference	Details

Host Biospecimen and Location

Host and Biospecimen	Status	Mean	Min	Max	Age	Sex	Health Condition	Data Source	Reference
Human	Detected and Quantified	0.5	0.0	1.0	Adult (>18 years old)	Both	Prostate Cancer	HMDB	19212411	details
Human Placenta	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Saliva	Detected but not Quantified				Adult (>18 years old)	Male	Normal	HMDB	22308371	details
Human Feces	Detected but not Quantified				Adult (>18 years old)	Both	Normal	HMDB	25037050	details
Human Bladder	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Brain	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Kidney	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Neuron	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Placenta	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Platelet	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Prostate	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Skeletal Muscle	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details
Human Testis	Detected but not Quantified				Not Specified	Not Specified	Normal	HMDB	34986597	details

External Links

Not Available

References

Synthesis Reference

Not Available

General References

Kato T, Shioiri T, Takahashi S, Inubushi T: Measurement of brain phosphoinositide metabolism in bipolar patients using in vivo 31P-MRS. J Affect Disord. 1991 Aug;22(4):185-90. doi: 10.1016/0165-0327(91)90064-y. [PubMed:1658103 ]
Ishii H, Umeda F, Hashimoto T, Nawata H: Increased inositol phosphate accumulation in platelets from patients with NIDDM. Diabetes Res Clin Pract. 1991 Oct;14(1):21-7. doi: 10.1016/0168-8227(91)90049-j. [PubMed:1660805 ]
Ross TS, Majerus PW: Inositol-1,2-cyclic-phosphate 2-inositolphosphohydrolase. Substrate specificity and regulation of activity by phospholipids, metal ion chelators, and inositol 2-phosphate. J Biol Chem. 1991 Jan 15;266(2):851-6. [PubMed:1845995 ]
King WG, Rittenhouse SE: Inhibition of protein kinase C by staurosporine promotes elevated accumulations of inositol trisphosphates and tetrakisphosphate in human platelets exposed to thrombin. J Biol Chem. 1989 Apr 15;264(11):6070-4. [PubMed:2703480 ]
Siess W: Evidence for the formation of inositol 4-monophosphate in stimulated human platelets. FEBS Lett. 1985 Jun 3;185(1):151-6. doi: 10.1016/0014-5793(85)80760-2. [PubMed:3996593 ]
Honchar MP, Olney JW, Sherman WR: Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science. 1983 Apr 15;220(4594):323-5. doi: 10.1126/science.6301005. [PubMed:6301005 ]
Chen WY, Ko FN, Lin CN, Teng CM: The effect of 3-[2-(cyclopropylamino)ethoxy]xanthone on platelet thromboxane formation. Thromb Res. 1994 Jul 1;75(1):81-90. doi: 10.1016/0049-3848(94)90142-2. [PubMed:8073410 ]
Grimminger F, Rose F, Sibelius U, Meinhardt M, Potzsch B, Spriestersbach R, Bhakdi S, Suttorp N, Seeger W: Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol. 1997 Aug 15;159(4):1909-16. [PubMed:9257856 ]
Bae YS, Cantley LG, Chen CS, Kim SR, Kwon KS, Rhee SG: Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 Feb 20;273(8):4465-9. doi: 10.1074/jbc.273.8.4465. [PubMed:9468499 ]
Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, Harden TK: Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. doi: 10.1124/mol.62.5.1249. [PubMed:12391289 ]
Kories C, Czyborra C, Fetscher C, Schneider T, Krege S, Michel MC: Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors? Naunyn Schmiedebergs Arch Pharmacol. 2003 May;367(5):524-31. doi: 10.1007/s00210-003-0713-8. Epub 2003 Mar 28. [PubMed:12669188 ]
Fourcade O, Simon MF, Litt L, Samii K, Chap H: Propofol inhibits human platelet aggregation induced by proinflammatory lipid mediators. Anesth Analg. 2004 Aug;99(2):393-8, table of contents. doi: 10.1213/01.ANE.0000123491.08697.CA. [PubMed:15271713 ]
Williams RS: Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1029-37. doi: 10.1016/j.pnpbp.2005.03.020. [PubMed:15950352 ]
Morou E, Georgoussi Z: Expression of the third intracellular loop of the delta-opioid receptor inhibits signaling by opioid receptors and other G protein-coupled receptors. J Pharmacol Exp Ther. 2005 Dec;315(3):1368-79. doi: 10.1124/jpet.105.089946. Epub 2005 Sep 13. [PubMed:16160084 ]
Jooste EH, Sharma A, Zhang Y, Emala CW: Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. Anesthesiology. 2005 Dec;103(6):1195-203. doi: 10.1097/00000542-200512000-00014. [PubMed:16306732 ]
Buccellati C, Sala A, Rossoni G, Capra V, Rovati GE, Di Gennaro A, Folco G, Colli S, Casagrande C: Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedica rboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations. J Pharmacol Exp Ther. 2006 May;317(2):830-7. doi: 10.1124/jpet.105.097170. Epub 2006 Jan 6. [PubMed:16399881 ]
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]

Showing metabocard for 1D-myo-inositol 1-phosphate (MMDBc0033096)

MOL for #<Metabolite:0x00007f09201ac1d0>

3D MOL for #<Metabolite:0x00007f09201ac1d0>

3D SDF for #<Metabolite:0x00007f09201ac1d0>

3D-SDF for #<Metabolite:0x00007f09201ac1d0>

PDB for #<Metabolite:0x00007f09201ac1d0>

3D PDB for #<Metabolite:0x00007f09201ac1d0>

SMILES for #<Metabolite:0x00007f09201ac1d0>

INCHI for #<Metabolite:0x00007f09201ac1d0>

Structure for #<Metabolite:0x00007f09201ac1d0>

3D Structure for #<Metabolite:0x00007f09201ac1d0>